Advanced Solid Tumors Cancer Clinical Trials

22 clinical trials for Advanced Solid Tumors Cancer across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) — RECRUITING
• A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. — RECRUITING · PHASE1
• PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer — RECRUITING · PHASE1
• ORB-021 In Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation — RECRUITING · PHASE1
• Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion. — NOT_YET_RECRUITING · PHASE1
• A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. — NOT_YET_RECRUITING · NA
• A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation — NOT_YET_RECRUITING · PHASE1
• First-In-Human Study of KHN922 for Injection — NOT_YET_RECRUITING · PHASE1
• A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors — COMPLETED · PHASE1
• A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of KC1086 in Patients With Advanced Solid Tumors — NOT_YET_RECRUITING · PHASE1
• Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Biological Age Predicts 90-Day Mortality in Advanced Cancer — COMPLETED
• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma — COMPLETED · PHASE1
• A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) — COMPLETED · PHASE1
• A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors — COMPLETED · PHASE1
• A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors — COMPLETED · PHASE1
• A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) — TERMINATED · PHASE1

Refine this search